Stockscreener 앱 받기
0.82
2.31%
0.0185
시간 외 거래:
.81
-0.010
-1.22%
전일 마감가:
$0.8015
열려 있는:
$0.7949
하루 거래량:
311.52K
Relative Volume:
0.42
시가총액:
$78.29M
수익:
$169.43M
순이익/손실:
$-186.01M
주가수익비율:
-0.4059
EPS:
-2.02
순현금흐름:
$70.07M
1주 성능:
+1.23%
1개월 성능:
-1.96%
6개월 성능:
-25.45%
1년 성능:
+2.38%
1일 변동 폭
$0.7804
$0.8299
1주일 범위
$0.778
$0.8299
52주 변동 폭
$0.7324
$1.798
애서티오 홀딩스 Stock (ASRT) Company Profile
명칭
Assertio Holdings Inc
전화
(224) 419-7106
주소
100 S. SAUNDERS ROAD, LAKE FOREST, IL
ASRT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASRT
Assertio Holdings Inc
|
0.82 | 78.29M | 169.43M | -186.01M | 70.07M | -2.02 |
|
ZTS
Zoetis Inc
|
171.91 | 77.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.68 | 43.77B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.43 | 42.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.81 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
127.12 | 13.51B | 612.78M | -86.37M | -62.91M | -0.87 |
애서티오 홀딩스 Stock (ASRT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-26 | 개시 | Maxim Group | Buy |
| 2024-07-03 | 개시 | H.C. Wainwright | Buy |
| 2022-11-07 | 개시 | Lake Street | Buy |
| 2018-11-30 | 다운그레이드 | Mizuho | Buy → Neutral |
애서티오 홀딩스 주식(ASRT)의 최신 뉴스
Keeping an Eye on Assertio Holdings Inc (ASRT) After Insider Trading Activity - Knox Daily
ASSERTIO HOLDINGS, INC. (NASDAQ: ASRT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Assertio Holdings, Inc. - ACCESS Newswire
Assertio Holdings Inc (ASRT) Shares Plummet Below 1-Year High - The News Heater
Short Interest in Assertio Holdings, Inc. (NASDAQ:ASRT) Decreases By 6.5% - MarketBeat
Investors in Assertio Holdings (NASDAQ:ASRT) have unfortunately lost 87% over the last five years - Yahoo Finance
Assertio Holdings faces Nasdaq delisting over share price rule - MSN
Assertio Holdings, Inc. (NASDAQ:ASRT) Sees Significant Decrease in Short Interest - MarketBeat
Jane Street Group LLC Sells 277,889 Shares of Assertio Holdings, Inc. (NASDAQ:ASRT) - Defense World
Geode Capital Management LLC Purchases 42,750 Shares of Assertio Holdings, Inc. (NASDAQ:ASRT) - Defense World
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Assertio Holdings Names New Chief Commercial Officer, Awards Major Stock Incentive Package - StockTitan
Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of Illinois against Assertio Holdings, Inc. - AccessWire
Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Up 14.1% in December - MarketBeat
Is Assertio Holdings (NASDAQ:ASRT) A Risky Investment? - Simply Wall St
Assertio appoints new independent director to board By Investing.com - Investing.com South Africa
Assertio appoints new independent director to board - Investing.com
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors - The Manila Times
Assertio Holdings Taps Former Astellas President Who Led $5B Sales Growth to Join Board - StockTitan
Assertio’s (ASRT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Assertio Therapeutics shares get buy rating on clinical trial results By Investing.com - Investing.com Canada
Assertio (NASDAQ:ASRT) Receives Buy Rating from HC Wainwright - MarketBeat
Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Down 11.5% in November - MarketBeat
Assertio reports positive Rolvedon trial results for breast cancer By Investing.com - Investing.com Australia
Assertio Announces Results of Rolvedon (Eflapegrastim-Xnst) Injection Same-Day Dosing Clinical Study - Marketscreener.com
Assertio reports positive Rolvedon trial results for breast cancer - Investing.com
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study - The Manila Times
Assertio's Rolvedon Shows Promising Clinical Data in Breast Cancer Trial with Same-Day Chemo Dosing - StockTitan
Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO - The Manila Times
Assertio Holdings Creates Transformation Office, Appoints New Leadership to Drive Growth Strategy - StockTitan
Assertio Holdings Inc (NASDAQ: ASRT): Blank Check On Growth? - Stocks Register
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - GlobeNewswire Inc.
Beam Therapeutics names Sravan K. Emany as new CFO - Investing.com
HC Wainwright Forecasts Stronger Earnings for Assertio - MarketBeat
Assertio shares hold price target, buy rating on stable Indocin share By Investing.com - Investing.com Canada
Assertio Holdings, Inc. (NASDAQ:ASRT) Shares Acquired by Empowered Funds LLC - Defense World
Assertio Holdings Q3 2024 Earnings Preview - MSN
Assertio stock gains amid Q3 earnings, clash with activist investor - MSN
Insider Buying: Assertio Holdings, Inc. (NASDAQ:ASRT) Director Acquires $60,000.00 in Stock - MarketBeat
Assertio Holdings director Heather Mason buys $60,000 in shares By Investing.com - Investing.com Nigeria
Assertio Holdings director Heather Mason buys $60,000 in shares - Investing.com
Assertio Holdings CEO Brendan O'Grady buys $9,950 in common stock - Investing.com India
Spectrum Pharma Faces Senate Probe Call Over Alleged Rolvedon Data Fraud | ASRT Stock News - StockTitan
Assertio Holdings Inc (ASRT) Quarterly 10-Q Report - Quartz
Assertio Holdings Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Assertio Holdings, Inc. (NASDAQ:ASRT) Q3 2024 Earnings Call Transcript - Insider Monkey
Assertio: Q3 Earnings Snapshot - The Washington Post
Assertio Therapeutics’ Q3 2024 Earnings Overview - TipRanks
Assertio stock gains amid Q3 earnings, clash with activist investor (NASDAQ:ASRT) - Seeking Alpha
Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
애서티오 홀딩스 (ASRT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.09%
자본화:
|
볼륨(24시간):